Different initiatives across Europe to enhance losartan utilization post generics: impact and implications (Q34304782)

1 August 2017

Different initiatives across Europe to enhance losartan utilization post generics: impact and implications (English)

1 reference

1 August 2017

1 reference

1

James C Moon

1 reference

1 August 2017

Brian Godman

2

0 references

Kathleen Bennett

object named as

Kathleen Bennett

5

0 references

Corrine Zara

11

object named as

Corinne Zara

1 reference

1 August 2017

Max Petzold

3

1 reference

1 August 2017

Samantha Alvarez-Madrazo

4

1 reference

1 August 2017

Iain Bishop

6

1 reference

1 August 2017

Anna Bucsics

7

1 reference

1 August 2017

Ulrik Hesse

8

1 reference

1 August 2017

Andrew Martin

9

1 reference

1 August 2017

Steven Simoens

10

1 reference

1 August 2017

Rickard E Malmström

12

1 reference

1 August 2017

8 October 2014

1 reference

Frontiers in Pharmacology

1 August 2017

1 reference

1 August 2017

5

1 reference

1 August 2017

219

1 reference

Multiple policies to enhance prescribing efficiency for established medicines in Europe with a particular focus on demand-side measures: findings and future implications

1 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4189327

Possible ways to enhance renin-angiotensin prescribing efficiency: Republic of Serbia as a case history?

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4189327

Impact of delisting ARBs, apart from losartan, on ARB utilisation patterns in Denmark: implications for other countries

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4189327

Reforms and initiatives in Scotland in recent years to encourage the prescribing of generic drugs, their influence and implications for other countries.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4189327

Antihypertensive efficacy of angiotensin receptor blockers as monotherapy as evaluated by ambulatory blood pressure monitoring: a meta-analysis.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4189327

Are prescribing initiatives readily transferable across classes: the case of generic losartan in Scotland?

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4189327

Assessing quality in cross-country comparisons of health systems and policies: towards a set of generic quality criteria

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4189327

Pharmacist-patient communication in Swedish community pharmacies

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4189327

Influence of multiple initiatives in Sweden to enhance ARB prescribing efficiency following generic losartan; findings and implications for other countries

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4189327

Ongoing initiatives in the Republic of Srpska to enhance prescribing efficiency: influence and future directions

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4189327

Proton pump inhibitors: potential cost reductions by applying prescribing guidelines

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4189327

Policies to enhance prescribing efficiency in europe: findings and future implications

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4189327

Influence of demand-side measures to enhance renin-angiotensin prescribing efficiency in Europe: implications for the future

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4189327

Getting better value from the NHS drug budget

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4189327

Comparing policies to enhance prescribing efficiency in Europe through increasing generic utilization: changes seen and global implications

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4189327

Insight into recent reforms and initiatives in Austria: implications for key stakeholders

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4189327

Policies to enhance the efficiency of prescribing in the Spanish Catalan region: impact and future direction

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4189327

Initial effects of a reimbursement restriction to improve the cost-effectiveness of antihypertensive treatment

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4189327

Soft regulations in pharmaceutical policy making: an overview of current approaches and their consequences

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4189327

Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden: global relevance

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4189327

Blood pressure lowering efficacy of angiotensin receptor blockers for primary hypertension

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4189327

Balancing Big Pharma's books

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4189327

Testing for serial correlation in least squares regression. I

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4189327

6 July 2018

Using clinical evidence

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4189327

Different versions of the anatomical therapeutic chemical classification system and the defined daily dose--are drug utilisation data comparable?

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4189327

Closing the gap between research and practice: an overview of systematic reviews of interventions to promote the implementation of research findings. The Cochrane Effective Practice and Organization of Care Review Group

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4189327

Interpreting the results of observational research: chance is not such a fine thing

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4189327

Measures to improve angiotensin receptor blocker prescribing efficiency in the UK: findings and implications.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4189327

Generic atypical antipsychotic drugs in Belgium: their influence and implications

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4189327

Influence of lifting prescribing restrictions for losartan on subsequent sartan utilization patterns in Austria: implications for other countries

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4189327

Initiatives to enhance the quality and efficiency of statin and PPI prescribing in the UK: impact and implications

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4189327

Coping with changes in the Defined Daily Dose in a longitudinal drug consumption database

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4189327

Evaluation of the clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a primary care setting: 2 years on.

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4189327

The ongoing regulation of generic drugs.

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4189327

Association of Treatment With Losartan vs Candesartan and Mortality Among Patients With Heart Failure

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4189327

Imperative to consider multiple initiatives to maximize prescribing efficiency from generic availability: case history from Abu Dhabi

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4189327

The ‘Wise List’- A Comprehensive Concept to Select, Communicate and Achieve Adherence to Recommendations of Essential Drugs in Ambulatory Care in Stockholm

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4189327

Examining product risk in context. Market withdrawal of zomepirac as a case study

28 October 2018

1 reference

12 December 2020

Segmented regression analysis of interrupted time series studies in medication use research

1 reference

12 December 2020

European countries with small populations can obtain low prices for drugs: Lithuania as a case history

1 reference

12 December 2020

What are the obstacles to generic substitution? An assessment of the behaviour of prescribers, patients and pharmacies during the first year of generic substitution in Sweden

1 reference

12 December 2020

Pharmacists’ experiences and attitudes regarding generic drugs and generic substitution: two sides of the coin

1 reference

12 December 2020

Multiple initiatives continue to enhance the prescribing efficiency for the proton pump inhibitors and statins in Scotland

1 reference

12 December 2020

Identifiers

DOI

10.3389/FPHAR.2014.00219

1 reference

1 August 2017

1 reference

1 August 2017

1 reference